Literature DB >> 24793732

The survival detriment of venous thromboembolism with epithelial ovarian cancer.

Camille C Gunderson1, Eric D Thomas2, Katrina N Slaughter2, Regina Farrell2, Kai Ding3, Ronni E Farris2, Jacob K Lauer2, LaToya J Perry2, D Scott McMeekin2, Kathleen N Moore2.   

Abstract

OBJECTIVE: The aim of this study is to evaluate the effect of venous thromboembolism (VTE) chronology with respect to surgery on survival with epithelial ovarian cancer (EOC).
METHODS: An IRB approved, retrospective review was performed of patients treated for Stage I-IV EOC from 1996 to 2011. Cox proportional hazards model was used to assess associations between VTE and the primary outcomes of progression free survival (PFS) and overall survival (OS). SAS 9.3 was used for statistical analyses.
RESULTS: 586 patients met study criteria. Median age was 63 years (range, 17-94); median BMI was 27.1 kg/m(2) (range, 13.7-67.0). Most tumors were high grade serous (68.3%) and advanced stage (III/IV, 75.4%). 3.7% had a preoperative VTE; 13.2% had a postoperative VTE. Upon multivariate analysis adjusting for age, stage, histology, performance status, and residual disease, preoperative VTE was predictive of OS (HR 3.1, 95% CI: 1.6-6.1, p=0.001) but not PFS (p=0.55). Postoperative VTE was associated with shorter PFS (HR 1.45, 95% CI: 1.04-2.02, p=0.03) and OS (HR 1.8, 95% CI: 1.3-2.6, p=0.001). When VTE timing was modeled, preoperative VTE (HR 3.5, 95% CI: 1.8-6.9, p<0.001) and postoperative VTE after primary therapy (HR 2.3, 95% CI: 1.4-3.6, p=0.001) were predictive of OS.
CONCLUSION: Preoperative and postoperative VTE appear to have a detrimental effect on OS with EOC. When modeled as a binary variable, postoperative VTE attenuated PFS; however, when VTE timing was modeled, postoperative VTE was not associated with PFS. It is unclear whether VTE is an inherent poor prognostic marker or if improved VTE prophylaxis and treatment may enable similar survival to patients without these events.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ovarian cancer; Survival; Venous thromboembolism

Mesh:

Year:  2014        PMID: 24793732     DOI: 10.1016/j.ygyno.2014.04.046

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

Review 1.  Prevention of venous thromboembolism in gynecologic oncology surgery.

Authors:  Emma L Barber; Daniel L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2016-11-25       Impact factor: 5.482

2.  Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review.

Authors:  Hongwei Shen; Jianhong Shang; Gang Niu; Jun Liu; Zeshan You; Shanyang He
Journal:  Oncol Lett       Date:  2015-07-15       Impact factor: 2.967

3.  Ovarian Cancer Presenting as Cryptogenic Stroke from Patent Foramen Ovale.

Authors:  Bindu R Potugari; Priyanka Priyanka; Sarah D Komanapalli; Richard J Mercier
Journal:  Clin Med Res       Date:  2019-07-19

Review 4.  A Systematic Review of the Guidelines on Venous Thromboembolism Prophylaxis in Gynecologic Oncology.

Authors:  Federico Romano; Giovanni Di Lorenzo; Guglielmo Stabile; Mariateresa Mirandola; Stefano Restaino; Patrizia Ianniello; Giuseppe Mirenda; Giuseppe Ricci
Journal:  Cancers (Basel)       Date:  2022-05-15       Impact factor: 6.575

5.  Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Authors:  Koji Matsuo; Kosei Hasegawa; Kiyoshi Yoshino; Ryusuke Murakami; Takeshi Hisamatsu; Rebecca L Stone; Rebecca A Previs; Jean M Hansen; Yuji Ikeda; Akiko Miyara; Kosuke Hiramatsu; Takayuki Enomoto; Keiichi Fujiwara; Noriomi Matsumura; Ikuo Konishi; Lynda D Roman; Hani Gabra; Christina Fotopoulou; Anil K Sood
Journal:  Eur J Cancer       Date:  2015-07-31       Impact factor: 9.162

Review 6.  Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  Biomark Cancer       Date:  2015-09-06

7.  Pulmonary thromboembolism secondary to pelvic thrombosis related to giant ovarian tumor.

Authors:  Alberto Amadasi; Salvatore Andreola; Marta Bianchi; Michele Boracchi; Guendalina Gentile; Francesca Maciocco; Matteo Marchesi; Riccardo Zoja
Journal:  Autops Case Rep       Date:  2019-01-14

8.  Dilemmas in anticoagulation and use of inferior vena cava filters in venous thromboembolism; a survey of Respiratory Physicians, Haematologists and Medical Oncologists and a review of the literature.

Authors:  Philip Craven; Ciara Daly; Nisha Sikotra; Tim Clay; Eli Gabbay
Journal:  Pulm Circ       Date:  2021-01-07       Impact factor: 3.017

9.  Risk factors, risk assessment, and prognosis in patients with gynecological cancer and thromboembolism.

Authors:  Xindan Wang; Jing Huang; Zhao Bingbing; Shape Li; Li Li
Journal:  J Int Med Res       Date:  2019-12-29       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.